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Introduction: Osteoarthritis (OA) is a chronic joint disease that usually occurs in older people 
and leads to pain and disabilities. OA treatment ranges from drug therapy to surgery. Drug and 
rehabilitation therapy are preferred over surgery, and, especially, there is a tendency toward 
compounds causing regenerative changes in the knee joint. In the present study, the effects of 
platelet-rich plasma (PRP) injection and prolotherapy (PRL) were examined on the level of 
pain and function of the knee joint in patients with OA.
Methodology: After fulfilling the inclusion criteria and signing the informed consent form, 
42 patients with knee OA were scheduled for intra-articular injection in the present randomized, 
double-blind, clinical trial. Following admission to the operating pain room, the condition 
of the patient’s knee was evaluated first via the Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) and, then, ultrasound-guided knee injection was done. Accord-
ingly, patients in the PRP therapy group received 7 mL PRP solution and those in the PRL 
group received 7 mL 25% dextrose. Using the WOMAC, levels of pain and knee function were 
evaluated and recorded for each patient immediately prior to the first injection as well as at 
1 month (immediately prior to the second injection), 2 months (a month after the second injec-
tion), and 6 months later. Data collected were analyzed using the SPSS v.20.
Results: During the first and second months, a rapid decrease in the overall WOMAC score 
was observed in both groups. The overall WOMAC score increased at the sixth month, but was 
lower than the overall WOMAC score in the first month. Statistical analysis indicated that the 
overall WOMAC score significantly decreased in both groups of patients over 6 months.
Conclusion: Results of the present study suggested a significant decrease in the overall 
WOMAC score of patients who undergo either PRP therapy or PRL. This positive change in 
the overall WOMAC score led to an improvement in the quality of life of patients with knee 
OA shortly after the first injection. PRP injection is more effective than PRL in the treatment 
of knee OA.
Keywords: knee osteoarthritis, platelet-rich plasma, prolotherapy, ultrasound
Introduction
Aging affects almost all physiological processes and causes changes in body composition. 
Recently, a triad encompassing simultaneous destruction of bone, muscle, and adipose 
tissues has been identified and named the osteosarcopenic obesity syndrome.1–3 
Osteopenia is the other problem that affects old people, especially in the neck of the 
femur or lumbar spine. Almost 80% of the American population over age 65 suffers 
from osteoarthritis (OA). OA is a chronic age-related joint disease that usually 
occurs in older people and damages articular cartilage and synovial joints. OA causes 
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significant disabilities and functional limitations in daily 
activities of affected patients. The most important symptoms 
include joint pain, stiffness, swelling, and decreased range 
of motion.1–4 Given the high incidence of this disease and 
costs of medical treatments, OA can be considered an eco-
nomic burden on society. Available treatments for OA can 
be classified into three groups: drug, nondrug/nonsurgical 
(eg, physical and rehabilitation therapy, occupational 
therapy, massage, exercise) – which are the primary line of 
treatment – and surgical therapies. The sequence of treat-
ment application begins with drug therapies and ends with 
surgical therapies.5,6 Injectable medications that can cause 
regenerative changes in tissue structure, manage and allevi-
ate OA symptoms, and help cope with the underlying tissue 
pathology are very important. This importance is due to the 
fact that these medicines are not only palliative but also 
reconstructive and preventive against replacement surgeries. 
Platelet-rich plasma (PRP) exists in this category. Platelets – 
besides contributing to the process of hemostasis – play 
different critical roles in the body. For example, following 
a tissue injury, platelets attract white blood cells to the site 
of injury and prevent damaged cells from being infected. 
Moreover, platelets contain a growth factor (ie, platelet-
derived growth factor [PDGF]) that increases the production 
of stem cells. This characteristic has made platelets attractive 
in OA treatment. Prolotherapy (PRL) is recommended for 
chronic musculoskeletal and painful joint conditions, such 
as knee OA.7–9 PRL involves the injection of an irritant solu-
tion into a damaged zone to encourage cell proliferation. 
Therefore, small amounts of an irritant solution (hypertonic 
dextrose injection) are injected occasionally into a damaged 
joint space. The exact mechanism of PRL action is not well 
understood yet; however, it is probably mediated by stimula-
tion of local healing cells via inflammation induction. The 
efficacy of PRL and other irritant factors for the treatment 
of knee OA has been reported in various studies.10–17 In the 
present study, the effectiveness of PRP therapy and PRL 
are compared in reducing pain intensity and symptoms of 
knee OA.
Methodology
This study was undertaken as a double-blind randomized clini-
cal trial after it was approved by the Ethics Committee of Iran 
University of Medical Sciences. The current study has been 
registered at the Clinical Trial Center (IRCT) with the code 
IRCT2014101810599N2. On fulfilling the inclusion criteria 
and signing the informed consent form, 44 patients with knee 
OA at the Rasul Akram Hospital were recruited as suitable 
candidates for intra-articular injection in the present random-
ized, double-blind clinical trial. Inclusion criteria were age 
range of 40–70 and stage 1 or 2 OA (based on the Kellgren–
Lawrence [KL] scale of the Radiological Society of America); 
exclusion criteria were rheumatoid arthritis or hemophilia, 
previous history of knee surgery, drug or alcohol addiction, 
and use of anticoagulant or nonsteroidal anti-inflammatory 
drugs (NSAIDs) in the previous 7 days. The primary informa-
tion, including age, gender, body mass index (BMI), stage of 
KL, and X-ray scan were recorded for all patients.
Based on a previous study, we calculated the sample size. 
In that study, the reported percentage of satisfaction in the 
PRP group at 6 months was equal to 75% (0.75), whereas 
this percentage was 10.8% (0.108) in the normal saline 
injection group. When we considered the alpha as 0.05 and 
beta as 0.1, with power of 95%, we calculated a sample size 
equal to 13 in each group. We finally enrolled 21 patients 
in each group.18
We used a block randomization method (block size of 
four) for determining which patient should be assigned to 
which group. Randomization remained unbroken during 
the study.
After admission of patients to the operating theater, the 
patient’s knee condition was evaluated on the basis of the 
Western Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC). The WOMAC measures five items for 
pain (score range 0–20), two for stiffness (score range 0–8), 
and 17 for functional limitations (score range 0–68). Thus, 
the possible WOMAC score is between 0 and 96.4
Following routine monitoring processes, such as exam-
ining blood pressure, heart rate, and an electrocardiogram, 
a 20-mL blood sample was drawn under sterile conditions 
and placed in specialized centrifuge kits for the preparation 
of PRP (Standard kit, Iran). Then, the blood was centrifuged 
for 20 minutes at a rotation speed of 3,200 rpm. The plasma 
was separated and recentrifuged for 5 minutes at a rotation 
speed of 1,500 rpm. Then, 7 mL of the separated plasma 
was prepared for intra-articular injection for patients in the 
PRP therapy group. Patients in the PRL group received 7 mL 
25% dextrose.
After administration of local anesthesia and placement of 
a multi-frequency linear probe of (6–13 MHz with a depth 
of 6 cm) an ultrasound machine (Sonosite, S-Nerve, South 
Korea) at the top of the patella, the intra-articular injection 
was administered under sterile conditions. Then, a 50 mm-
long 22-gauge needle (Visioplex needle, Vygon Company, 
France) was inserted into the knee joint at the upper outer 
quadrant of the patella under ultrasonographic guidance 
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via the Inplane technique. Then, the prepared solution was 
injected into the knee joint; this was done with every patient, 
with neither the patient nor the physician aware of the content 
of the syringes. Patients remained under medical care for 
an hour and were then discharged if no complications were 
detected. The same procedure was repeated 1 month later 
for all patients. In case of postprocedural pain, paracetamol 
was prescribed.
Using the WOMAC, levels of pain and knee function 
were evaluated and recorded for each patient at specified time 
points – immediately prior to the first injection, 1 month later 
(immediately prior to the second injection), 2 months later 
(a month after the second injection), and 6 months later. The 
investigator and the data analyzer were not aware of patient 
allocation.
statistical analyses
Data collected were analyzed using SPSS v. 20. We com-
pared the data and outcome variables (physical activity, pain, 
stiffness, and WOMAC) between treatment groups (PRP vs 
PRL) and in successive sessions. Based on the nature of the 
variables (all are discrete variables) and number of classes, 
we used parametric tests for analysis of physical activity, 
pain, and WOMAC between groups and nonparametric 
tests for stiffness. With regard to physical activity, pain, 
and WOMAC, we first assessed the normality of data by 
the Kolmogorov–Smirnov test (K–S test) and determined 
that all of them were normally distributed – thus, we used 
parametric tests for analysis. Furthermore, we used mixed-
model analysis of variance (ANOVA) for analysis of physical 
activity, pain, and WOMAC between two groups in suc-
cessive time sessions. The post hoc test was applied, and 
Bonferroni correction was considered for interpretation of 
P-values. For analysis of data from each treatment group in 
successive sessions separately, we used repeated-measures 
ANOVA, and all pairwise comparisons (for different time 
sessions) were accomplished. For comparison of two treat-
ment groups in similar time periods, we used the Student 
t-test. For stiffness, we used nonparametric tests (Friedman 
test for comparison of different time sessions in each treat-
ment groups) and Wilcoxon signed rank test for pairwise 
comparisons. Similar time sessions between two treatment 
groups were compared by Mann–Whitney U test. P-values 
were considered significant at 0.05, and they were inter-
preted on the basis of Bonferroni correction. All baseline 
data were compared between groups by chi-square, t-, and 
Mann–Whitney U tests. Normality of data were assessed by 
the K–S test at first.
Results
Forty-two patients (21 in each group) with knee OA were 
enrolled in the study. No significant difference was observed 
in demographic and baseline characteristics between the two 
groups (Table 1).
The severity of knee OA was assessed using the patients’ 
WOMAC scores (ie, the sum of functional limitations, stiffness, 
and pain-level scores). There was no statistically significant 
between-group difference with regard to the WOMAC score 
and its subscales (including physical activity [or functional 
limitation], pain, and stiffness) before treatment when baseline 
values were collected (all P-values $0.73; Table 2).
Mean physical activity (or functional limitation) scores 
recorded at baseline values are mentioned in Table 3. As we 
can see, in the PRL group, the physical activity score dropped 
from 47.8 before treatment to 19.6 in the second month and 
then rose to 22.8 in the sixth month. A similar pattern was 
seen for PRP, for which the score dropped from 47.3 before 
treatment to 25 in the second month to rise to 27.8 in the sixth 
month. In detail, all pairwise comparisons of physical activity 
in different time periods for both groups were statistically 
significant. In addition, in the mixed-model ANOVA, the 
Table 1 Comparison of demographic and baseline characteristics 
between two groups
Patient demographic characteristics P-value
Age (year) PrP 65.5±6.64 0.53
Prl 64.3±5.31
BMI (kg/m2) PrP 28.6±1.8 0.68
Prl 28.3±1.9
Kl score PrP 2.47±0.5 0.76
Prl 2.42±0.5
sex (male/female) PrP 10/11 0.76
Prl 11/10
Abbreviations: BMI, body mass index; Kl, Kellgren–lawrence; Prl, prolotherapy; 
PrP, platelet-rich plasma.
Table 2 Comparison of patient WOMAC scores and its subscales 
between two groups before the intervention
Patient WOMAC scores before the 
intervention
P-value
Functional limitation Prl 47.3±6.7 0.81
PrP 47.8±4.7
Pain level Prl 14.6±1.4 0.76
PrP 14.8±1.5
stiffness Prl 5.2±1.3 0.73
PrP 5.4±1.2
WOMAC score Prl 67.1±7.9 0.75
PrP 67.9±7.3
Abbreviations: Prl, prolotherapy; PrP, platelet-rich plasma; WOMAC, Western 
Ontario and McMaster Universities Osteoarthritis Index.
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main effect of time and interaction of time with treatment 
group was statistically significant, whereas the P-value (0.11) 
of the main effect of the treatment group was borderline. 
Given the fact that a comparison of two groups in similar 
time sessions was statistically significant in the second and 
sixth months (better results for PRP; and not significant at 
pretreatment and in the first month), the borderline P-value 
for the treatment group in the mixed-model ANOVA could 
be attributed somehow to similar results of physical activity 
between the groups at months 0 and 1.
The mean pain scores at baseline have been mentioned 
in Table 4. As we can see, in the PRL group, the pain score 
dropped from 14.6 before treatment to 7.1 in the second month 
and then rose to 8 in the sixth month. A similar pattern was 
seen for PRP; its score dropped from 14.8 before treatment 
to 5.4 in the second month and then rose to 6.2 in the sixth 
month. In detail, all pairwise comparisons of pain in different 
time periods for both groups were statistically significant. In 
addition, in mixed-model ANOVA, the main effect of time 
and interaction of time with treatment group was statistically 
significant, whereas the P-value (0.056) of the main effect 
of the treatment group was borderline. Given the fact that 
the comparison of two groups in similar time sessions was 
statistically significant in the second and sixth months (better 
results for PRP, but not in the pretreatment phase and at the 
first month); the borderline P-value for the treatment group in 
mixed-model ANOVA could be attributed somehow to similar 
results of pain between the two groups at months 0 and 1.
The mean stiffness score from the baseline values have 
been mentioned in Table 5. As we can see, in PRL group, 
the stiffness score dropped from 5.2 before treatment to 2.6 
in the second month and then rose to 3 in the sixth month. 
A similar pattern was seen for PRP – the stiffness score 
dropped from 5.4 before treatment to 2.1 in the second month 
Table 3 Comparison of physical activity (functional limitation) between two groups in successive months
Repeated-
measures test
Pairwise comparisons*
Pretreatment First 
month
Second 
month
Sixth 
month
All
Prl 47.3±6.7 31±6.3 25±5.5 27.8±5.2 0.001 All of P-values were #0.001 except for 
comparison between (1 vs 6) that was 0.004
PrP 47.8±4.7 30.3±7.6 19.6±7.2 22.8±7.9 0.001 All P-values were #0.001
P-value of between group 
comparison in similar times
0.81 0.74 0.009 0.021
Mixed-model AnOVA P-values
group 0.11
Time 0.001 All P-values were 0.001
Time*group 0.007
Notes: *Pairwise comparisons included comparisons at different time sessions including preprocedural data (0), first-month data (1), second-month data (2), and sixth-month 
data (6); these were as follows: (0 vs 1), (0 vs 2), (0 vs 6), (1 vs 2), (1 vs 6), and (2 vs 6).
Abbreviations: AnOVA, analysis of variance; Prl, prolotherapy; PrP, platelet-rich plasma.
Table 4 Comparison of pain between two groups in successive months
Repeated-
measures test
Pairwise comparisons*
Pretreatment First 
month
Second 
month
Sixth 
month
All
Prl 14.6±1.4 9.5±2.3 7.1±1.7 8±1.6 0.001 All P-values were #0.001 except for comparison 
between (1 vs 6), which was 0.004
PrP 14.8±1.5 9.2±2.7 5.4±1.8 6.2±2.1 0.001 All P-values were 0.001 except for comparison 
between (1 vs 6), which was 0.015 and 
comparison between (2 vs 6) that was 0.022
P-value of between-group 
comparison at similar time points
0.76 0.71 0.002 0.003
Mixed-model AnOVA P-values
group 0.056
Time 0.001 All P-values were #0.001
Time*group 0.003
Notes: *Pairwise comparisons included comparisons at different time sessions including preprocedural data (0), first-month data (1), second-month data (2), and sixth-month 
data (6); these were as follows: (0 vs 1), (0 vs 2), (0 vs 6), (1 vs 2), (1 vs 6), and (2 vs 6).
Abbreviations: AnOVA, analysis of variance; Prl, prolotherapy; PrP, platelet-rich plasma.
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to rise to 2.5 in the sixth month. In detail, pairwise compari-
sons of stiffness for the PRL group at different time periods 
were significant except for the comparison of first versus 
sixth and of second versus sixth month. For PRP, pairwise 
comparisons at different time periods were all significant, 
except for the second versus the sixth month which was 
borderline. In addition, pairwise comparison of similar time 
sessions between the two groups showed that all differences 
were nonsignificant; however, the contrast between the two 
groups in the second and sixth months were quite borderline, 
and favored better results for PRP.
The mean WOMAC scores at baseline are reported in 
Table 6. In the PRL group, the WOMAC score dropped 
from 67.1 before treatment to 34.8 in the second month, 
and then rose to 38.7 in the sixth month. A similar pattern 
was seen for PRP, for which the score dropped from 67.9 
before treatment to 27.1 in the second month and then rose 
to 31.4 in the sixth month. Briefly, all pairwise comparisons 
of WOMAC in different time periods for both groups were 
statistically significant. In addition, in the mixed-model 
ANOVA, the main effect of time and interaction of time with 
the treatment group was statistically significant, whereas the 
P-value (0.097) of the main effect of the treatment group was 
borderline. Given the fact that the comparison of the two 
groups at similar time sessions was statistically significant in 
the second and sixth months (better results for PRP, although 
not in the pretreatment and first month time points), the bor-
derline P-value for the treatment group in the mixed-model 
ANOVA could be attributed somehow to similar results of 
WOMAC between the two groups at months 0 and 1.
Discussion
Various noninvasive and minimally invasive methods have 
been used for the treatment of knee OA. The most preva-
lent treatments are physical and rehabilitation therapy, 
administration of NSAIDs and glucosamine, and, in case 
Table 5 Comparison of stiffness scores between the two groups in successive months
Repeated-
measures test
Pairwise comparisons*
Pretreatment First 
month
Second 
month
Sixth 
month
All
Prl 5.2±1.3 3.2±1.1 2.6±0.7 3±0.7 0.001 All P-values were 0.001 except for comparison 
between (1 vs 2), which was 0.018, comparison 
between (1 vs 6), which was 0.28, and 
comparison between (2 vs 6), which was 0.14
PrP 5.4±1.2 3.3±1.1 2.1±0.7 2.5±0.8 0.001 All of P-values were #0.001 except for 
comparison between (2 vs 6), which was 0.071
P-value of between-group 
comparison at similar time points
0.73 0.65 0.055 0.091
Notes: *Pairwise comparisons included comparisons at different time points including of preprocedural data (0), first-month data (1), second-month data (2), and sixth-month 
data (6); these were as follows: (0 vs 1), (0 vs 2), (0 vs 6), (1 vs 2), (1 vs 6), and (2 vs 6).
Abbreviations: Prl, prolotherapy; PrP, platelet-rich plasma.
Table 6 Comparison of WOMAC between two groups in successive months
Repeated-
measures test
Pairwise comparisons*
Pretreatment First 
month
Second 
month
Sixth 
month
All
Prl 67.1±7.9 43.8±8.2 34.8±6.9 38.7±6.6 0.001 All P-values were 0.001 except for the 
comparison between (2 vs 6), which was 0.003
PrP 67.9±7.3 42.9±10.85 27.1±9.1 31.4±10.2 0.001 All P-values were 0.001 except for the 
comparison between (1 vs 6), which was 0.002
P-value of between-group 
comparison in similar times
0.74 0.77 0.004 0.009
Mix model AnOVA P-values
group 0.097
Time 0.001 All P-values were 0.001
Time*group 0.001
Notes: *Pairwise comparisons included comparisons at different time points including of preprocedural data (0), first-month data (1), second-month data (2), and sixth-month 
data (6); these were as follows: (0 vs 1), (0 vs 2), (0 vs 6), (1 vs 2), (1 vs 6), and (2 vs 6).
Abbreviations: Prl, prolotherapy; PrP, platelet-rich plasma; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
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of ineffectiveness with these preliminary measures, intra-
articular injection of hyaluronic acid, corticosteroid, PRP, 
PRL, and growth hormone as well as radiofrequency have 
been undertaken.4,12 Several studies have been conducted to 
examine the effectiveness of PRP therapy in reducing symp-
toms and pain associated with OA.15–18 Activated platelet 
results in the release of some mediators, such as growth 
factors and cytokines. In vivo studies showed that PRP may 
cause increased proliferation and differentiation of chondro-
cytes as well. Furthermore, PRP may have anti-inflammatory 
effects through inhibition of the NF-κB pathway.19 Each 
milliliter of PRP solution contains 1.5–2 million platelets, 
causing a 5-fold increase in platelets and growth factors. 
Hyperosmolar dextrose, as a PRL agent, increases levels of 
PDGF. PRL acts as an irritant which has been shown to be 
effective in the repair of connective tissue injuries. PRL is 
more effective than PRP therapy in the treatment of enthesitic 
inflammations.20
Results of the present trial indicated that PRP therapy is 
more effective than PRL over time. Moreover, it was shown 
that PRP therapy can significantly decrease pain, functional 
limitations, and stiffness in patients with knee OA for up to 
24 weeks. In this study, the overall WOMAC score improve-
ment was 54%. Finally, 60% of the examined patients 
experienced a 50% improvement during a 24-week period. 
In fact, the improvement process had an upward trend for up 
to 8 weeks after the intervention, and the maximum improve-
ment was observed in that period; thereafter, there was a slight 
but nonsignificant decline in scores until Week 24. This might 
be due to an excessive use of the knee joint secondary to pain 
relief and is considered an underestimation of the results. 
In this study, PRP therapy was more effective than PRL in 
improving the quality of life of patients with knee OA.
Chang et al compared the effects of PRP and hyaluronic 
acid injection for knee pain and found that PRP injection 
is more effective for patients with damaged articular car-
tilage than was hyaluronic acid. Moreover, patients with 
mild OA responded better to PRP injection than those with 
severe OA.5
In a systematic review, PRL conferred a positive and 
significant beneficial effect in the treatment of knee OA 
and, in the current study, PRL had significant effectiveness 
as well.20 Intra-articular injection of PRP has induced a sig-
nificant diminishing of degenerative articular inflammatory 
changes. Short-term effects of PRP in the treatment of knee 
OA have been examined in previous studies. These studies 
indicated that PRP injection is more effective than hyaluronic 
acid and placebo injections. Another study compared the 
effects of a single dose of PRP injection with corticosteroid 
injection on the severity of knee OA symptoms and showed 
that PRP reduces joint pain to a greater extent and for a lon-
ger duration. In the abovementioned study,16,21 pain and OA 
severity were measured via the visual analog scale, whereas 
a more comprehensive measure tool (ie, the WOMAC) was 
used in the current study. In another study, a significant 
difference was reported between PRP and hyaluronic acid 
groups of patients with WOMAC scores, where patients 
treated by PRP injection showed better functional scores. 
In a systematic review, the administration of PRP was 
compared against that of corticosteroids, hyaluronic acid, 
oral NSAIDs, and placebos. The results showed that PRP is 
an effective treatment for knee OA, even up to 12 months. 
Nevertheless, the frequent use of PRP injection increases the 
possibility of adverse reactions.21–23 Studies have shown that 
the use of growth factors can be effective in the treatment of 
localized cartilage defects, such as in OA. Although, there 
is still a need for further research in this area, it has been 
proven that the deficiency of the growth hormone increases 
the severity of articular cartilage pathology in patients with 
OA.4,8 According to the results of this study and previous 
studies, PRP injection can be useful for OA patients whose 
knee condition has not been improved via other therapeutic 
procedures, such as physiotherapy, exercise therapy, and 
other medications or injections.
This study had some limitations such as: lack of a control 
group receiving placebo; lack of morphological assessment 
of cartilage, soft tissue, and structures in and around the knee 
joint; small sample size; and limited timeframe for patient 
assessment. PRP therapy needs a centrifuge machine and 
specific kits and, thus, costs are higher than for PRL; there-
fore, decisions about the application of this more expensive 
treatment must be made properly.
Conclusion
In the present study, compared to PRL, PRP injection was 
more effective in reducing pain, stiffness, and functional 
limitations in OA patients after 2 months and for up to 
6 months of follow-up. No significant side effects was 
observed.
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